Literature DB >> 6414752

First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.

K Hall, N Otten, J Irvine-Meek, M Leroux, D Budnick, M Verma, S S Seshia.   

Abstract

The serum concentration-time curve of valproic acid was followed in 25 children after single oral doses of the drug and at steady-state. Total body clearance (CL), half-life (t 1/2), and apparent volume of distribution (Vd) were calculated from the terminal portion of the curve and from the area under the serum concentration-time curve (AUC). The CL and Vd were significantly greater at steady-state (0.42 +/- 0.20 ml/min/kg and 0.231 +/- 0.067 L/kg, respectively) than after a single dose (0.32 +/- 0.13 ml/min/kg and 0.191 +/- 0.055 L/kg, respectively). This difference was most pronounced in patients with valproic acid dosage increases in excess of 20% and no change in their concurrent anticonvulsant therapy between the single-dose and steady-state study periods. The t 1/2 was not significantly different between the 2 study periods. There was a significant correlation between age and both CL and Vd after single doses and at steady-state. The t 1/2 did not appear to be age related. These results suggest that the adequacy of the dosage regimen must be determined during maintenance therapy rather than extrapolated from data obtained after a single dose. Re-evaluation of therapy as the child grows older may also be necessary in view of the age-related differences in valproic acid pharmacokinetics which this study has demonstrated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414752     DOI: 10.2165/00003088-198308050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  11 in total

1.  Pharmacokinetics and bioavailability of sodium valproate.

Authors:  U Klotz; K H Antonin
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

2.  Comparison of gas-liquid chromatography and EMIT assay for serum valproic acid.

Authors:  M Leroux; D Budnik; K Hall; J Irvine-Meek; N Otten; S Seshia
Journal:  Clin Biochem       Date:  1981-04       Impact factor: 3.281

Review 3.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

4.  Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.

Authors:  G J Schapel; R G Beran; C J Doecke; W J O'Reilly; P A Reece; R H Rischbieth; L N Sansom; P E Stanley
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications.

Authors:  P L Morselli; R Franco-Morselli; L Bossi
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

6.  Disposition of sodium valproate in epileptic patients.

Authors:  E Perucca; G Gatti; G M Frigo; A Crema; S Calzetti; D Visintini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

7.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

8.  Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity.

Authors:  W E Dodson; V Tasch
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

9.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

10.  Valproic acid dosage and plasma protein binding and clearance.

Authors:  A T Bowdle; I H Patel; R H Levy; A J Wilensky
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

View more
  5 in total

1.  Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation.

Authors:  J A Armijo; J L Herranz; R Arteaga; R Valiente
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

2.  Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.

Authors:  Jack M Su; Xiao-Nan Li; Patrick Thompson; Ching-Nan Ou; Ashish M Ingle; Heidi Russell; Ching C Lau; Peter C Adamson; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

Review 3.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.